|Bid||9.60 x 900|
|Ask||9.74 x 1000|
|Day's Range||9.39 - 10.09|
|52 Week Range||0.62 - 13.44|
|Beta (5Y Monthly)||3.07|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 17, 2021 - Mar 22, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.75|
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will present a company overview at the SVB Leerink 10th Annual Global Healthcare Conference on Friday, February 26th, 2021 at 1:40 pm ET.
The big shareholder groups in Curis, Inc. ( NASDAQ:CRIS ) have power over the company. Institutions often own shares in...
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the first patient has been dosed in its Phase 1 trial evaluating CA-4948, a novel, small molecule IRAK4 kinase inhibitor, in combination with ibrutinib, a BTK inhibitor, in patients with relapsed or refractory (R/R) hematologic malignancies.